SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
Clin. transl. oncol. (Print)
; 23(5): 969-979, mayo 2021. tab
Article
in English
| IBECS
| ID: ibc-221237
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. Tumor testing for BRCA1 and BRCA2 is recommended for patients with metastatic prostate cancer, also considering a broad panel to guide decisions and genetic counseling. In symptomatic metastatic patients, castration should be stared to palliate symptoms and prolong survival. In high-risk or high-volume metastatic hormone-naïve patients, castration should be combined with docetaxel, abiraterone, enzalutamide or apalutamide. Radiotherapy to the primary tumor combined with systemic therapy is recommended in low-volume mHNPC patients. In patients with non-metastatic castration-resistant tumors, risk stratification can define the frequency of imaging. Adding enzalutamide, darolutamide or apalutamide to these patients prolongs metastasis-free and overall survival, but potential adverse events need to be taken into consideration. The choice of docetaxel, abiraterone or enzalutamide for treating metastatic castration-resistant patients depends on previous therapies, with cabazitaxel being also recommended after docetaxel. Olaparib is recommended in BRCA1/BRCA2 mutated castration-resistant patients after progression on at least one new hormonal therapy. Aggressive variants of prostate cancer respond to platinum-based chemotherapy. To optimize treatment efficiency, oncologists should incorporate all of these advances into an overall therapeutic strategy (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Prostatic Neoplasms
Limits:
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article
Institution/Affiliation country:
Fundación Instituto Valenciano de Oncología/Spain
/
Hospital General Universitario Gregorio Marañón/Spain
/
Hospital Provincial de Castellón/Spain
/
Hospital Universitari Santa Creu i San Pau/Spain
/
Hospital Universitario Lucus Augusti/Spain
/
Hospital Universitario Puerta de Hierro-Majadahonda/Spain
/
Hospital Universitario Virgen de la Victoria y Regional de Mälaga/Spain
/
Instituto Imas12/Spain
/
Maimonides Institute for Biomedical Research of Córdoba (IMIBIC)/Spain
/
Universitat Autònoma de Barcelona/Spain